Relixir Pharmaceuticals Private Limited, a active private limited company, was established on 14 February 2011 in Hyderabad, Telangana, India. Engaging in drug formulation & development within the manufacturing sector, it holds CIN: U24100TG2011PTC072584. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹10.50 Cr and a paid-up capital of ₹10.50 Cr.
It upholds a compliant status. Employing 60 professional, Its leadership includes Anil Kumar Devanapalli Ramaya (Director), Vinutha Mandula (Director). Past directors included Thirupathi Reddy Lakkireddy, Nischal Yachamaneni, Navaratan Kakani. It holds no open charges and ₹26.81 Cr settled loans. Its latest AGM occurred on 30 September 2023, with the balance sheet filed on 31 March 2023. It is based at P.No. 24, 1-89/A/8/1/24, Trendz Jr, 4B, Gaffor Nagar, Madhapur, Hyderabad, Telangana, 500081.
U24100TG2011PTC072584
072584
14 February 2011
₹10.50 Cr
₹10.50 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Relixir Pharmaceuticals Private Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Anil Kumar Devanapalli Ramaya | Director | 14 Feb 2011 | Current |
| Vinutha Mandula | Director | 10 Oct 2014 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Director | 22 Dec 2016 | Past |
| Pramod Abcsdd | Director | 22 Oct 2019 | Past |
| Pramod Abcsdd | Company Secretary | - | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Relixir Pharmaceuticals Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 43.65% decrease. The company also saw a substantial fall in profitability, with a 57.4% decrease in profit. The company's net worth moved up by a moderate rise of 8.24%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2022, Relixir Pharmaceuticals had a promoter holding of 95.80% and a public holding of 4.20%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹0
₹268,100,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 30 Apr 2022 | Others | ₹1.45 Cr | Satisfied |
| 23 Nov 2020 | Others | ₹7.00 M | Satisfied |
| 16 Aug 2017 | Others | ₹24.66 Cr | Satisfied |
Explore comprehensive loan charge details -
Relixir Pharmaceuticals has a workforce of 60 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Relixir Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Relixir Pharmaceuticals's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity Relixir Pharmaceuticals Private Limited last Annual general meeting of members was held on 30 Sep 2023 as per latest MCA records. was completed.
Progress on Relixir Pharmaceuticals Private Limited has filed its annual Financial statements for the year ended 31 Mar 2023 with Roc Hyderabad. was documented.
A charge registered on 30 Apr 2022 via Charge ID 100581030 with Others was fully satisfied on 23 Mar 2023. was recorded as a recent event.
Progress on A charge registered on 23 Nov 2020 via Charge ID 100394867 with Others was fully satisfied on 23 Mar 2023. was documented.
A charge registered on 16 Aug 2017 via Charge ID 100131752 with Others was fully satisfied on 23 Mar 2023. was recorded as a recent event.
Progress on A charge with Others amounted to Rs. 1.45 Cr with Charge ID 100581030 was registered on 30 Apr 2022. was documented.
The CIN of Relixir Pharmaceuticals Private Limited is U24100TG2011PTC072584.
Relixir Pharmaceuticals Private Limited is headquartered at P.No. 24, 1-89/A/8/1/24, Trendz Jr, 4B, Gaffor Nagar, Madhapur, Hyderabad, Telangana, 500081.
Relixir Pharmaceuticals Private Limited was incorporated on 14 February 2011.
The current directors of Relixir Pharmaceuticals Private Limited are
The primary industry of Relixir Pharmaceuticals Private Limited is Manufacturing.
Relixir Pharmaceuticals Private Limited is unlisted.
The authorized capital of Relixir Pharmaceuticals Private Limited is ₹10.50 Cr, and the paid-up capital is ₹10.50 Cr.
The compliance status of Relixir Pharmaceuticals Private Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX